FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/03/082667 [Registered on: 18/03/2025] Trial Registered Prospectively
Last Modified On: 04/03/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Determination and comparision of effective dose of Propofol combined with Fentanyl and Propofol combined with Remifentanyl in order to find the optimal sedation dose in sedation in Upper Gastrointestinal endoscopic procedures 
Scientific Title of Study   Optimal Sedation Analgesia In Upper Gastrointestinal Endoscopic Interventions Determination and Comparison of Median Effective Target Concentration of Propofol In Combination With Fentanyl versus Remifentanil PERFS 
Trial Acronym  PERFS 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Shikhar More 
Designation  Consultant 
Affiliation  Consultant, Department of Onco-Anaesthesia and Pain, Tata Medical Center, Kolkata, India 
Address  Department of Oncoanaesthesiology and Pain, Phase 1, 2nd floor, 14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India

Kolkata
WEST BENGAL
700160
India 
Phone  8521890962  
Fax    
Email  shikharmore@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Shikhar More 
Designation  Consultant 
Affiliation  Consultant, Department of Onco-Anaesthesia and Pain, Tata Medical Center, Kolkata, India 
Address  Department of Oncoanaesthesiology and Pain, Phase 1, 2nd floor, 14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India

Kolkata
WEST BENGAL
700160
India 
Phone  8521890962  
Fax    
Email  shikharmore@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Shikhar More 
Designation  Consultant 
Affiliation  Consultant, Department of Onco-Anaesthesia and Pain, Tata Medical Center, Kolkata, India 
Address  Department of Oncoanaesthesiology and Pain, Phase 1, 2nd floor, 14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India

Kolkata
WEST BENGAL
700160
India 
Phone  8521890962  
Fax    
Email  shikharmore@gmail.com  
 
Source of Monetary or Material Support  
Tata Medical Center, Kolkata. 14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India 
 
Primary Sponsor  
Name  Dr Shikhar More 
Address  Tata Medical Center, Kolkata 14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Shikhar More  Tata Medical Center  Endoscopy unit, Phase 2, 14 MAR (E-W), New Town, Rajarhat, Kolkata 700 160, West Bengal, India.
North Twentyfour Parganas
WEST BENGAL 
8521890962

shikharmore@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Tata Medical Center-Institutional Review Board  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: O||Medical and Surgical,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Fentanyl Bolus  Fentanyl boluses will be administered along with propofol target controlled infusion for analgesic component. 
Intervention  Remifentanil TCI.  Remifentanil will be administered along with propofol target controlled infusion for analgesic component. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  70.00 Year(s)
Gender  Both 
Details  Patients aged 18-70 years undergoing upper GI
endoscopic interventions (ERCP and
EUS-FNA)

ASA (American Society of Anesthesiologists)
physical status I-III. 
 
ExclusionCriteria 
Details  History of allergy to study drugs.
Severe cardiovascular, respiratory, hepatic or renal disease.
Pregnancy and lactation.
BMI less than 18 or more than 35
Psychiatric illness or liver dysfunction leading to altered sensorium
Documented OSA
Anticipated difficult airway 
 
Method of Generating Random Sequence   Permuted block randomization, fixed 
Method of Concealment   Case Record Numbers 
Blinding/Masking   Participant, Investigator and Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
Incidence of sedation related adverse events (SRAE).  Periprocedure 
 
Secondary Outcome  
Outcome  TimePoints 
ED50 and ED90 of propofol in both groups.
Incidence of unsuccessful sedation
Recovery time
Endoscopist satisfaction
Patient satisfaction
Mean total Propofol consumption
 
Periprocedural 
 
Target Sample Size   Total Sample Size="280"
Sample Size from India="280" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   15/04/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Background and purpose

Endoscopic retrograde cholangiopancreaticography (ERCP) and endoscopic ultrasound (EUS) are complex and time consuming procedures that require optimal sedation and analgesia. Propofol target controlled infusion (TCI) is commonly used at our institution in combination with either fentanyl bolus or remifentanil TCI. However, there is a paucity in literature regarding the median effective effect site concentration (EC50, Ce) of propofol for sedation in such time consuming endoscopic procedures, especially when used with remifentanil TCI. This study is being proposed to compare propofol fentanyl and propofol remifentanil regimens when used via TCI at the predetermined median effective target

concentration (EC50) of propofol. The study will be done in two parts. Part 1 will determine the EC50 and EC95 of propofol with fentanyl and remifentanil combinations. Part 2 of the study will compare the two regimens in terms of efficacy of sedation and incidence of sedation related adverse effects. 


Methodology

The study will be done in two parts

Part 1 Determination of EC50 and EC90 of propofol

Participants will be randomly allotted to one of two groups:

Group F Fentanyl bolus of 0.5 mcg/kg

Group R Remifentanil TCI at Ce of 2 ng/mL

The EC50 and EC90 of propofol will be determined for both groups using the Dixon up and down sequential allocation method. The first participant in both will receive an initial effect site concentration (Ce) of 2 mcg/ml. The subsequent participants initial starting Ce will be determined based on the response of the previous participant. Propofol Ce will be increased in step size of 0.5 mcg/mL for rescue in case of unsuccessful sedation.

In case of unsuccessful sedation or positive response, the starting Ce of Propofol will be increased by a step size of 0.5 mcg/mL in the subsequent patient. In case of successful sedation or negative response, the starting Ce of Propofol will be decreased by 0.5 mcg/mL in the subsequent patient. 

Successful sedation is defined as

MOASS score 2 

Patient does not exhibit gag, cough, purposeful bodily movement throughout the procedure.

Part 2

 Randomised controlled trial between the two groups at the determined EC90 of propofol.

Participants will be randomly allotted to one of two groups

Group F Fentanyl bolus of 0.5 mcg/kg

Group R Remifentanil TCI at Ce of 2 ng/mL

Both groups of participants will receive propofol TCI at the determined EC90. The primary outcome is the incidence of adverse effects. The secondary outcome will be

Recovery Time - Time to regain MOASS  5 after stopping TCI.

Endoscopist satisfaction (4 point Likert scale -  excellent, good, acceptable and poor)

Patient satisfaction (4 point Likert scale -  excellent, good, acceptable and poor)

Mean total propofol consumption - in mg/kg.



 
Close